MIF1 and MIF2 Myostatin Peptide Inhibitors as Potent Muscle Mass Regulators

MIF1 and MIF2 Myostatin Peptide Inhibitors as Potent Muscle Mass Regulators

Show other versions (1)

The use of peptides as drugs has progressed over time and continues to evolve as treatment paradigms change and new drugs are developed. Myostatin (MSTN) inhibition therapy has shown great promise for the treatment of muscle wasting diseases. Here, we report the MSTN-derived novel peptides MIF1 (10-...

Full description

Bibliographic Details
Main Authors: Ahmad, K. (Author), Ahmad, S.S (Author), Ali, S. (Author), Baig, M.H (Author), Choi, I. (Author), Lee, E.J (Author), Lim, J.H (Author), Park, S.-Y (Author), Shaikh, S. (Author)
Format: Article
Language:English
Published: MDPI 2022
Subjects:
muscle regeneration
myogenesis
myostatin
peptides
skeletal muscle
Online Access:View Fulltext in Publisher

Similar Items

Similar Items